UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 64

Sortiert nach

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies

Trends in molecular medicine, 2020-03, Vol.26 (3), p.296-310

2020

Volltextzugriff (PDF)

Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis

Cancer cell, 2015-11, Vol.28 (5), p.653-665

2015

Volltextzugriff (PDF)

Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists

Cancer cell, 2013-01, Vol.23 (1), p.23-34

2013

Volltextzugriff (PDF)

Itraconazole Inhibits Angiogenesis and Tumor Growth in Non-Small Cell Lung Cancer

Cancer research (Chicago, Ill.), 2011-11, Vol.71 (21), p.6764-6772

2011

Volltextzugriff (PDF)

Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer

Molecular cancer therapeutics, 2015-03, Vol.14 (3), p.642-648

2015

Volltextzugriff (PDF)

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2013-05, Vol.8 (5), p.619-623

2013

Volltextzugriff (PDF)

Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models

Clinical & translational immunology, 2022, Vol.11 (2), p.e1373-n/a

2022

Volltextzugriff (PDF)

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

Clinical cancer research, 2012-06, Vol.18 (11), p.3090-3099

2012

Volltextzugriff (PDF)

Hedgehog Pathway Inhibition Radiosensitizes Non-Small Cell Lung Cancers

International journal of radiation oncology, biology, physics, 2013-05, Vol.86 (1), p.143-149

2013

Volltextzugriff (PDF)

Proteome‐wide analysis of T‐cell response to BK polyomavirus in healthy virus carriers and kidney transplant recipients reveals a unique transcriptional and functional profile

Clinical & translational immunology, 2020, Vol.9 (1), p.e01102-n/a

2020

Volltextzugriff (PDF)

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis

JCI insight, 2020-10, Vol.5 (20)

2020

Volltextzugriff (PDF)

Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients

The Journal of experimental medicine, 2020-10, Vol.217 (10)

2020

Volltextzugriff (PDF)

Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells

The Journal of clinical investigation, 2016-12, Vol.126 (12), p.4640-4653

2016

Volltextzugriff (PDF)

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma

Journal for immunotherapy of cancer, 2021-12, Vol.9 (12), p.e003441

2021

Volltextzugriff (PDF)

Correction: Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients

The Journal of experimental medicine, 2022-11, Vol.219 (11)

2022

Volltextzugriff (PDF)

Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma

Clinical cancer research, 2020-11, Vol.26 (22), p.6028-6038

2020

Volltextzugriff (PDF)

Molecular signature of Epstein-Barr virus infection in MS brain lesions

Neurology : neuroimmunology & neuroinflammation, 2018-07, Vol.5 (4), p.e466-e466

2018

Volltextzugriff (PDF)

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: (Trends in Molecular Medicine, 26:3 p:296-310, 2020)

Trends in molecular medicine, 2021-04, Vol.27 (4), p.410-411

2021

Volltextzugriff (PDF)

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma

Molecular cancer therapeutics, 2017-11, Vol.16 (11), p.2375-2386

2017

Volltextzugriff (PDF)

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis

JCI insight, 2018-11, Vol.3 (22)

2018

Volltextzugriff (PDF)

A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists

Molecular cancer therapeutics, 2012-01, Vol.11 (1), p.165-173

2012

Volltextzugriff (PDF)

Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis

Multiple sclerosis journal - experimental, translational and clinical, 2021-04, Vol.7 (2), p.20552173211019772-20552173211019772

2021

Volltextzugriff (PDF)

Itraconazole Side Chain Analogues: Structure–Activity Relationship Studies for Inhibition of Endothelial Cell Proliferation, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, and Hedgehog Signaling

Journal of medicinal chemistry, 2011-10, Vol.54 (20), p.7363-7374

2011

Volltextzugriff (PDF)

246 Disruption of the cytokine signaling checkpoint CIS enhances serial-killing and anti-tumor activity of CAR-engineered γδ T cells

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A285-A285

2023

Volltextzugriff (PDF)

684 Assay development and quantitative detection of ADI-001, a CD20-targeted γδ1 CAR T therapy, using AlloCell, a universal assay for monitoring of off-the-shelf allogeneic cell therapies

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A777-A777

2023

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(63)
Dissertationen
(1)

Sprache

Englisch
(64)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(23)
Humans
(15)
Animals
(12)
Oncology
(12)
Mice
(11)
Lymphocytes
(9)
Immunotherapy
(8)
Cell Line, Tumor
(7)
Xenograft Model Antitumor Assays
(7)
Antigens
(6)
Medicine, Research & Experimental
(6)
Research & Experimental Medicine
(6)
Antineoplastic Agents - Pharmacology
(5)
Female
(5)
Cell Biology
(4)
Cytokines
(4)
Cytotoxicity
(4)
Immunology
(4)
Male
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies

Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis

Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists

Itraconazole Inhibits Angiogenesis and Tumor Growth in Non-Small Cell Lung Cancer

Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

Hedgehog Pathway Inhibition Radiosensitizes Non-Small Cell Lung Cancers

Proteome‐wide analysis of T‐cell response to BK polyomavirus in healthy virus carriers and kidney transplant recipients reveals a unique transcriptional and functional profile

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis

Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients

Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma

Correction: Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients

Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma

Molecular signature of Epstein-Barr virus infection in MS brain lesions

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: (Trends in Molecular Medicine, 26:3 p:296-310, 2020)

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis

A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists

Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis

Itraconazole Side Chain Analogues: Structure–Activity Relationship Studies for Inhibition of Endothelial Cell Proliferation, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, and Hedgehog Signaling

246 Disruption of the cytokine signaling checkpoint CIS enhances serial-killing and anti-tumor activity of CAR-engineered γδ T cells

684 Assay development and quantitative detection of ADI-001, a CD20-targeted γδ1 CAR T therapy, using AlloCell, a universal assay for monitoring of off-the-shelf allogeneic cell therapies

Suchergebnisse filtern